

Resource Summary Report

Generated by [dkNET](#) on Jul 28, 2026

PE anti-mouse CD3

RRID:AB_312663

Type: Antibody

Proper Citation

BioLegend Cat# 100206, RRID:AB_312663

Antibody Information

URL: http://antibodyregistry.org/AB_312663

Proper Citation: BioLegend Cat# 100206, RRID:AB_312663

Target Antigen: CD3

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PE anti-mouse CD3

Description: This monoclonal targets CD3

Target Organism: mouse

Clone ID: Clone 17A2

Antibody ID: AB_312663

Vendor: BioLegend

Catalog Number: 100206

Alternative Catalog Numbers: 100205

Record Creation Time: 20250820T060932+0000

Record Last Update: 20250820T232522+0000

Ratings and Alerts

No rating or validation information has been found for PE anti-mouse CD3.

No alerts have been found for PE anti-mouse CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 61 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Yu H, et al. (2025) Single-cell and spatial transcriptomics reveal the pathogenesis of chronic granulomatous disease in a natural model. Cell reports, 44(5), 115612.

Ma X, et al. (2025) BFAR Promotes Neutrophil Infiltration and Immunosuppressive Reprogramming through the PRP19-YBX1 Axis to Induce Immune Evasion in Gastric Cancer. Cancer immunology research, 13(12), 2037.

Wei X, et al. (2025) Immune imprinting blunts omicron pathogenicity fluctuations and highlights the essential role of cellular immunity in SARS-CoV-2 infection. Cell reports, 44(6), 115784.

Tang Q, et al. (2025) Gut bacterial L-lysine alters metabolism and histone methylation to drive dendritic cell tolerance. Cell reports, 44(1), 115125.

Prakash A, et al. (2025) Mitochondrial-activity-driven hematopoietic stem cell fate and lineage choice is first established in the aorta-gonad-mesonephros. Cell reports, 44(10), 116296.

Zhang G, et al. (2025) Myeloid-lineage-specific membrane protein LRRC25 suppresses immunity in solid tumor and is a potential cancer immunotherapy checkpoint target. Cell reports, 44(5), 115631.

Steinberg M, et al. (2025) Cannabidiol directly targets the immunosuppressive activity of regulatory myeloid cells in tumors. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 192, 118697.

Adar L, et al. (2025) Keratinocyte differentiation transcription factor ZNF750 coordinates the development of epidermal immunocytes. Cell reports, 44(12), 116648.

Gu C, et al. (2025) An innovative engineered IL-10 monomer strengthens T cell-mediated anti-tumor responses through anti-PD-1 cis-delivery. Cell reports. Medicine, 102515.

Chen H, et al. (2025) Postprandial parasympathetic signals promote lung type 2 immunity. Neuron, 113(5), 670.

Song Q, et al. (2025) Bifidobacterium animalis suppresses non-small cell lung cancer progression and modulates tumor immunity through indole-3-acetic acid. Cell reports, 44(8), 116132.

Zhang Y, et al. (2025) Cancer cells co-opt an inter-organ neuroimmune circuit to escape immune surveillance. Cell, 188(24), 6754.

Qian Y, et al. (2025) Metformin hijacks AMPK-ERK1/2 signaling to trigger a pathogenic "selection trap" and thymic atrophy. Cell reports, 45(1), 116762.

Restaino AC, et al. (2024) TUMOR-INFILTRATING NOCICEPTOR NEURONS PROMOTE IMMUNOSUPPRESSION. bioRxiv : the preprint server for biology.

Li JJ, et al. (2024) Differentiation route determines the functional outputs of adult megakaryopoiesis. Immunity, 57(3), 478.

Xu S, et al. (2024) Development of a PAK4-targeting PROTAC for renal carcinoma therapy: concurrent inhibition of cancer cell proliferation and enhancement of immune cell response. EBioMedicine, 104, 105162.

Gao KM, et al. (2024) Endothelial cell expression of a STING gain-of-function mutation initiates pulmonary lymphocytic infiltration. Cell reports, 43(4), 114114.

Pritchard JE, et al. (2024) Non-canonical Hedgehog signaling mediates profibrotic hematopoiesis-stroma crosstalk in myeloproliferative neoplasms. Cell reports, 43(1), 113608.

Lin Y, et al. (2024) Effects of gut microbiota on immune checkpoint inhibitors in multi-cancer and as microbial biomarkers for predicting therapeutic response. Med (New York, N.Y.), 100530.

Guo P, et al. (2024) Engineered probiotic ameliorates ulcerative colitis by restoring gut microbiota and redox homeostasis. Cell host & microbe, 32(9), 1502.